Inside the unconventional FDA panel that could reshape the peptide industry
An unconventional FDA panel is assessing the safety and efficacy of previously-banned peptides. It could open up a multibillion-dollar market.
An unconventional FDA panel is assessing the safety and efficacy of previously-banned peptides. It could open up a multibillion-dollar market.
This article was originally published at: https://www.businessinsider.com/rfk-convenes-unusual-fda-...